Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSolvonis Therap Regulatory News (SVNS)

Share Price Information for Solvonis Therap (SVNS)

Share Price is delayed by 15 minutes
Get Live Data
0.175    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.01 (5.882%)
Market Cap: £11.91m
SVNS Live PriceLast checked at - London Stock Exchange

Intraday Solvonis Therap Share Chart

Holding(s) in Company

7 Apr 2025 07:00

RNS Number : 8860D
Solvonis Therapeutics PLC
07 April 2025
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BMD1Z199

Issuer Name

Solvonis Therapeutics PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of financial instruments

3. Details of person subject to the notification obligation

Name

Spreadex LTD

City of registered office (if applicable)

St. Albans

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

02-Apr-2025

6. Date on which Issuer notified

03-Apr-2025

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

5.988900

1.132400

7.121300

163500000

Position of previous notification (if applicable)

6.576900

0.392000

6.968900

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BMD1Z199

137500000

5.988900

Sub Total 8.A

137500000

5.988900%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

CFD/Spread Bet

26000000

1.132400

Sub Total 8.B1

26000000

1.132400%

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

Sam Meisel01727 895138Spreadex is an FCA regulated provider of spread betting and CFD trading. Founded in 1999, Spreadex gives both retail and professional traders the opportunity to trade over 10,000 global markets, including UK small caps. For more information see www.spreadex.com/financials.

12. Date of Completion

03-Apr-2025

13. Place Of Completion

UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUNOKRVOUSRAR
12
Date   Source Headline
22nd Jun 20267:00 amRNSAnnounces Positive Bridging Data Supporting
19th Jun 20269:39 amRNSSolvonis Announces Result of AGM
27th May 202612:00 pmRNSNotice of Annual General Meeting
5th May 20267:00 amRNS-RCSO Speaks at National Research Meeting
29th Apr 20267:00 amRNSFinal Results
22nd Apr 20267:00 amRNS-RAppointment of Water Tower Research
20th Apr 20268:32 amRNS-RUS CNS Executive Order
8th Apr 20267:00 amRNSGranted U.S. Patent from PTSD Discovery Programme
31st Mar 20267:00 amRNSGranted U.S. Patent from PTSD Discovery Programme
10th Mar 20267:00 amRNSSVN-114 selected for PTSD discovery programme
28th Jan 20267:00 amRNSExpansion of SVN-015 into depression
7th Jan 20267:00 amRNSUS Patent allowance for PTSD discovery programme
22nd Dec 20257:00 amRNSResearch and Development Update - Q4 2025
22nd Dec 20257:00 amRNSResearch and Development Update – Q4 2025
3rd Dec 20257:00 amRNSSVN-015 accepted into US NIDA funded programme
31st Oct 20253:59 pmRNSTotal Voting Rights
31st Oct 20257:00 amRNSCorporate Structure Update and Issue of Options
27th Oct 20257:00 amRNSAppoints global biopharma leader Paul Carter
16th Oct 20257:00 amRNSRaises £1.25 Million to Accelerate Programmes
30th Sep 20257:00 amRNSHalf-year Report
28th Aug 20257:00 amRNSSolvonis secures exclusive CNS collaboration
13th Aug 20253:03 pmRNS-RMedia Coverage: Small Cap Idea profile
12th Aug 20257:00 amRNSSVN-SDN-14 PTSD - Positive pre-clinical results
31st Jul 20254:30 pmRNSTotal Voting Rights
22nd Jul 20257:00 amRNSTranslational Bridging Studies
18th Jul 202511:03 amRNSExercise of warrants
14th Jul 20257:00 amRNS-RSolvonis Chair to speak at Lucid Capital Markets
11th Jul 20257:00 amRNS£1m subscription to accelerate AI drug discovery
8th Jul 20257:00 amRNSHolding(s) in Company
27th Jun 20252:38 pmRNSAGM Statement
27th Jun 20258:54 amRNSHolding(s) in Company
26th Jun 202510:21 amRNS-RInitiation of Research Coverage
23rd Jun 20257:00 amRNSAllowance of U.S. patent covering AI-supported CNS
11th Jun 20257:30 amRNSInitiation of AI supported CNS drug discovery
5th Jun 20257:00 amRNSSynthesis of development candidate for SVN-SDN-014
3rd Jun 20254:30 pmRNSNotice of Annual General Meeting
3rd Jun 20257:00 amRNSAppointment of Prof. David Nutt as CSO
2nd Jun 202511:58 amRNSHolding(s) in Company
30th May 20255:00 pmRNSTotal Voting Rights
29th May 20253:11 pmRNSHolding(s) in Company
29th May 202512:02 pmRNSHolding(s) in Company
29th May 202510:30 amRNSHolding(s) in Company
29th May 20257:00 amRNS-RPresentation at Mello2025
28th May 20257:30 amRNSHolding(s) in Company
28th May 20257:00 amRNSCompletion of the acquisition of Awakn
21st May 20253:24 pmRNSPublication of a Prospectus
16th May 20257:31 amRNSResult of placing
15th May 20254:53 pmRNSProposed equity fundraising via ABB
28th Apr 202511:30 amRNSResult of General Meeting
23rd Apr 20257:00 amRNSProposed acquisition of Awakn approved
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.